Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer
NCT06747481 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 323
Last updated 2024-12-24
Summary
Pancreatic cancer has an incidence of 1,401,450 new cases diagnosed annually worldwide and is the third leading cause of cancer-related death in Spain. This disease is associated with a poor prognosis, reflected by a 5-year survival rate of less than 5% when all stages are grouped together.
Several prognostic factors for pancreatic cancer have been identified. The most relevant include preoperative levels of carbohydrate antigen 19-9 (CA 19.9), surgical margins after resection, venous and/or arterial vascular involvement, and histopathological features such as affected locoregional lymph nodes, or perineural and lymphovascular invasion. Among all these factors, perineural invasion may be the primary independent factor affecting prognosis, particularly in patients with relatively favorable pathological features.
The identification of perineural invasion before surgery could influence the clinical management of these patients. It may facilitate risk stratification, allowing the identification of patients who would benefit most from neoadjuvant treatments or more aggressive surgical procedures, such as vascular resections. However, perineural involvement is very difficult to detect preoperatively.
Only a few studies have analyzed the possible relationship between CA 19.9 and perineural invasion, and their results are inconsistent. Alternatively, some studies have demonstrated the utility of preoperative multidetector computed tomography in detecting extrapancreatic perineural invasion. However, these radiological tests are still not useful for directly detecting microscopic perineural invasion, especially in early stages.
On the other hand, in recent years, evidence has supported that the systemic inflammatory response may play an important role in the prognosis of different malignancies. Among these inflammatory markers, the neutrophil-to-lymphocyte ratio (NLR) has gained prominence. Regarding pancreatic cancer, many studies suggest that elevated preoperative NLR levels are associated with a worse prognosis. However, no studies have yet been published analyzing a possible relationship between this inflammatory marker and perineural invasion.
The main objective of this study is to correlate the neutrophil-to-lymphocyte ratio (NLR) and CA 19.9 with histopathologically confirmed perineural invasion and, in this way, investigate these data as potential preoperative markers of perineural invasion in pancreatic cancer. Our working hypothesis is that preoperative NLR and CA 19.9 are potential markers of perineural invasion.
As secondary objectives, we aim to study the effect of neoadjuvant therapy on inflammatory markers (NLR) and tumor markers (CEA and CA 19.9) in pancreatic cancer.
Conditions
- Pancreatic Cancer, Adult
- Perineural Invasion
- Neutrophil-to-Lymphocyte Ratio
- CA 19.9
Sponsors & Collaborators
-
University of Las Palmas de Gran Canaria
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-01-01
- Primary Completion
- 2024-12-31
- Completion
- 2025-09-30
Countries
- Spain
Study Locations
More Related Trials
-
The Effect of Albumin Value, HALP Score, and LCR Value on Predicting Survival and Recurrence in Patients With Pancreatic Adenocarcinoma
NCT06553040 ·Status: COMPLETED
-
Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer
NCT03199144 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
NCT01531712 ·Status: TERMINATED ·Phase: PHASE2
-
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
NCT05356039 ·Status: RECRUITING
-
Perfusion Assessment With Contrast-Enhanced EUS in Locally Advanced and Metastatic Pancreatic Cancer
NCT03513198 ·Status: UNKNOWN
-
Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas
NCT05234450 ·Status: UNKNOWN
-
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
NCT02072616 ·Status: TERMINATED ·Phase: NA
-
New Predictive Marker for Pancreatic Cancer Using CA19-9 and Fecal Elastase
NCT05923567 ·Status: ACTIVE_NOT_RECRUITING
-
Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients
NCT02456051 ·Status: TERMINATED
-
Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRI
NCT05511116 ·Status: UNKNOWN
-
Early Recurrence After Surgery for Pancreatic Cancer
NCT07241676 ·Status: ENROLLING_BY_INVITATION
-
Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia
NCT04753229 ·Status: COMPLETED
-
Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer
NCT05745415 ·Status: COMPLETED
-
Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma
NCT06478056 ·Status: COMPLETED ·Phase: NA
-
Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy
NCT06006728 ·Status: COMPLETED
-
Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer
NCT01389440 ·Status: COMPLETED ·Phase: PHASE2
-
INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors
NCT04436679 ·Status: COMPLETED
-
Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma
NCT01129167 ·Status: COMPLETED
-
Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
NCT03673423 ·Status: UNKNOWN
-
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
NCT01692873 ·Status: COMPLETED ·Phase: NA
-
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
NCT06172036 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma
NCT02974764 ·Status: COMPLETED
-
Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma
NCT05248750 ·Status: RECRUITING
-
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
NCT05287347 ·Status: WITHDRAWN
-
Pancreas Screening in High Risk Individuals
NCT07012018 ·Status: NOT_YET_RECRUITING